Citadel Advisors
GMAB icon

Citadel Advisors’s Genmab GMAB Stock Holding History

Citadel Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,200
Closed -$407K – 13444
2025
Q4 		$407K Buy
13,200
+3,000
+29% +$93.5K ﹤0.01% 9502
2025
Q3 		$313K Sell
10,200
-16,600
-62% -$405K ﹤0.01% 10265
2025
Q2 		$554K Sell
26,800
-11,200
-29% -$230K ﹤0.01% 8403
2025
Q1 		$744K Buy
38,000
+25,200
+197% +$529K ﹤0.01% 7614
2024
Q4 		$267K Buy
12,800
+4,600
+56% +$101K ﹤0.01% 9892
2024
Q3 		$200K Sell
8,200
-4,800
-37% -$128K ﹤0.01% 10151
2024
Q2 		$327K Sell
13,000
-800
-6% -$22.7K ﹤0.01% 8967
2024
Q1 		$413K Buy
13,800
+11,000
+393% +$323K ﹤0.01% 8803
2023
Q4 		$89.2K Sell
2,800
-100
-3% -$3.14K ﹤0.01% 11071
2023
Q3 		$102K Sell
2,900
-500
-15% -$19.1K ﹤0.01% 10867
2023
Q2 		$129K Sell
3,400
-4,900
-59% -$195K ﹤0.01% 10552
2023
Q1 		$313K Buy
8,300
+6,100
+277% +$234K ﹤0.01% 9294
2022
Q4 		$93.2K Buy
+2,200
New +$90.7K ﹤0.01% 11325
2021
Q4 		– Sell
-8,000
Closed -$350K – 14168
2021
Q3 		$350K Sell
8,000
-45,800
-85% -$2.06M ﹤0.01% 10713
2021
Q2 		$2.2M Sell
53,800
-83,300
-61% -$3.21M ﹤0.01% 6357
2021
Q1 		$4.5M Buy
137,100
+93,800
+217% +$3.53M ﹤0.01% 4485
2020
Q4 		$1.76M Buy
43,300
+26,300
+155% +$983K ﹤0.01% 5621
2020
Q3 		$622K Buy
17,000
+7,600
+81% +$275K ﹤0.01% 6893
2020
Q2 		$319K Sell
9,400
-2,700
-22% -$73.6K ﹤0.01% 7819
2020
Q1 		$256K Buy
+12,100
New +$270K ﹤0.01% 7590

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Citadel Advisors's GMAB Position: Q1 2026 in Review

Citadel Advisors sold out of Genmab (GMAB) in Q1 2026, closing a stake of 19,102 shares — an estimated $572K sold.

Citadel Advisors first reported a position in GMAB in Q3 2019 and held it in 24 quarters. The position peaked at $86.7M in Q1 2025. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Citadel Advisors reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 19,102 Genmab shares in Q1 2026, an estimated $572K.
  • Citadel Advisors first reported a position in Genmab in Q3 2019 and held it in 24 quarters.
  • Citadel Advisors's Genmab position peaked at $86.7M in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.